Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Tarsus Pharmaceuticals (TARS) Receivables - Net (2021 - 2025)

Tarsus Pharmaceuticals has reported Receivables - Net over the past 5 years, most recently at $85.1 million for Q4 2025.

  • Quarterly results put Receivables - Net at $85.1 million for Q4 2025, up 81.9% from a year ago — trailing twelve months through Dec 2025 was $85.1 million (up 81.9% YoY), and the annual figure for FY2025 was $85.1 million, up 81.9%.
  • Receivables - Net for Q4 2025 was $85.1 million at Tarsus Pharmaceuticals, up from $72.6 million in the prior quarter.
  • Over the last five years, Receivables - Net for TARS hit a ceiling of $85.1 million in Q4 2025 and a floor of $17000.0 in Q1 2022.
  • Median Receivables - Net over the past 5 years was $27.1 million (2021), compared with a mean of $30.2 million.
  • Biggest five-year swings in Receivables - Net: plummeted 99.93% in 2022 and later skyrocketed 31441.18% in 2023.
  • Tarsus Pharmaceuticals' Receivables - Net stood at $20.0 million in 2021, then tumbled by 99.92% to $17000.0 in 2022, then surged by 97670.59% to $16.6 million in 2023, then soared by 181.33% to $46.8 million in 2024, then soared by 81.9% to $85.1 million in 2025.
  • The last three reported values for Receivables - Net were $85.1 million (Q4 2025), $72.6 million (Q3 2025), and $58.3 million (Q2 2025) per Business Quant data.